Developing a Systemically Delivered TLR2 Agonist for Cancer Immunotherapy
Time: 3:30 pm
day: Conference Day 2
Details:
- Understand the mechanistic rationale for pursuing TLR2 agonists in CPI resistant solid tumor indications
- Review the safety and tolerability profile of AXA-042 demonstrated in the first-in-human clinical trial
- Translational lessons from the clinic: impact of TLR2 target engagement on clinical safety and response biomarkers
